Phytochem Remedies IPO FY26 – ₹38 Cr Fresh Issue, 94% PAT Growth, 15x P/E, and a Corrugated Box Wearing a Pharma Name Tag
1. At a Glance – The Headline That Pretends to Be Pharma but Ships Cardboard
Phytochem Remedies (India) Limited walked into the IPO party wearing a name that sounds like Ayurveda meets chemistry, but once you lift the curtain, it’s pure corrugated cardboard drama. No syrups, no tablets, no miracle herbs — just good old brown boxes holding biscuits, shampoos, pesticides, and pharma products that actually do the medicinal heavy lifting. The company is hitting the SME market with a fixed-price IPO of ₹98 per share, aiming to raise ₹38.22 crore entirely through fresh equity. Pre-IPO market cap sits around ₹115.39 crore, which puts it squarely in the “SME but acting confident” category.
Financially, the company has suddenly discovered the accelerator pedal. Between FY24 and FY25, revenue grew a modest 12%, but profit after tax decided to hit the gym and bulk up by a massive 94%. EBITDA margins expanded, ROE crossed a spicy 34%, and the post-IPO P/E cools off to around 15x, which sounds reasonable until you remember this is a corrugated box manufacturer operating in one of the most brutally competitive and fragmented industries known to mankind. Add to that a debt-to-equity ratio north of 1.4, and suddenly the cardboard starts feeling a little flimsy. Curious already? Good. Let’s open the box.
2. Introduction – When a Cardboard Company Names Itself Like a Pharma Brand
Let’s address the elephant in the corrugated room. The name “Phytochem Remedies” sounds like it should be selling herbal cough syrups or immunity boosters endorsed by a yoga guru. Instead, it manufactures corrugated boxes. This mismatch alone has confused more investors than a CA exam question with missing data. But names aside, this is a real manufacturing company with over two decades of operational history, incorporated back in 2002, quietly doing its job from Jammu while staying under most radars.
The IPO comes at a time when SME investors are oscillating between wild optimism and deep trauma from recent listings. On one hand, packaging demand is structurally linked to FMCG, food, pharma, and e-commerce. On the other hand, corrugated boxes are the vanilla ice cream of manufacturing — everyone makes them, margins are thin, and differentiation is harder than finding a seat in a general compartment train.
Phytochem Remedies claims consistency, customer stickiness, and sustainability-focused expansion. The numbers do show improvement, especially in profitability, but the suddenness of the jump raises eyebrows. Is this operational excellence finally kicking in after 20 years, or is FY25 a one-season blockbuster that may not get a sequel? That’s the question this IPO forces investors to ask. Ready to dig deeper, or already side-eyeing the balance sheet?
3. Business Model – WTF Do They Even Do? (Spoiler: Boxes, Lots of Boxes)
Phytochem Remedies manufactures corrugated boxes and boards — the unsung heroes of modern consumption. Every biscuit packet, shampoo bottle, pesticide can, or pharma strip needs a box to travel safely from factory to distributor. That’s where Phytochem steps in. The company produces 3-ply, 5-ply, and 7-ply corrugated boxes, along with printed boxes, corrugated rolls, pads, and sheets. Basically, if it’s brown, layered, and recyclable, they probably make it.
Operations are spread across two manufacturing units in Bari Brahmana, Jammu. Unit 1 has an allocated area of 43,360 sq. ft., and Unit 2 is much larger at 1,73,440 sq. ft. The interesting bit? Utilisation is still relatively low. Unit 1 uses about 12,000 sq. ft., and Unit 2 around 55,000 sq. ft. Translation: there is room to grow without immediately buying land on Mars.
The customer base spans FMCG, food & beverages, pharmaceuticals, pesticides, and automotive ancillaries. This diversification reduces dependency on any single sector, but it doesn’t eliminate pricing pressure. Corrugated packaging is a volume game. Customers negotiate hard, raw material prices fluctuate, and loyalty lasts only until someone else offers a cheaper box. With just 51 employees as of September 30, 2025, this is a lean operation, but scalability will test whether systems are robust or just jugaad-powered. So far, so good — but how long can cardboard margins hold their shape?
4. Financials Overview – The Table That Makes You Go “Hmm”
The company has published half-yearly results up to September 30, 2025. Since this is not explicitly labelled as quarterly results, EPS annualisation follows the half-yearly rule.
Financial Performance Comparison (₹ in Crore)
Metric
Latest Period (Sep 2025)
Same Period Last Year
Previous Period
YoY %
QoQ %
Revenue
25.01
16.50
36.81*
51.6%
-32.0%
EBITDA
6.72
3.40
8.69*
97.6%
-22.7%
PAT
3.75
1.50
4.48*
150.0%
-16.3%
EPS (₹)
3.19
1.35
3.81*
136.3%
-16.3%
*Previous period refers to FY25 full-year figures, used here only for directional context.
Witty takeaway? Profits are sprinting, revenue is jogging, and consistency is still tying its shoelaces. Annualised EPS (half-yearly) comes to roughly ₹6.38, which matches the post-IPO disclosure. At ₹98 per share, the valuation doesn’t scream madness, but it
